Fredun Pharmaceuticals Dirección

Dirección controles de criterios 4/4

El CEO de Fredun Pharmaceuticals' es Daulat Medhora , nombrado en Jan 2010, tiene una permanencia de 14.25 años. compensación anual total es ₹1.20M, compuesta por 100% salario y 0% primas, incluidas acciones y opciones de la empresa. posee directamente un 30.01% de las acciones de la empresa, por valor de ₹1.19B. La antigüedad media del equipo directivo y de la junta directiva es de 9.5 años y 8.6 años, respectivamente.

Información clave

Daulat Medhora

Chief Executive Officer (CEO)

₹1.2m

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	14.3yrs
Participación del CEO	30.0%
Permanencia media de la dirección	9.6yrs
Promedio de permanencia en la Junta Directiva	8.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Daulat Medhora en comparación con los beneficios de Fredun Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	₹156m
Dec 31 2023	n/a	n/a	₹183m
Sep 30 2023	n/a	n/a	₹130m
Jun 30 2023	n/a	n/a	₹123m
Mar 31 2023	₹1m	₹1m	₹108m
Dec 31 2022	n/a	n/a	₹58m
Sep 30 2022	n/a	n/a	₹83m
Jun 30 2022	n/a	n/a	₹70m
Mar 31 2022	₹1m	₹1m	₹63m
Dec 31 2021	n/a	n/a	₹39m
Sep 30 2021	n/a	n/a	₹33m
Jun 30 2021	n/a	n/a	₹23m
Mar 31 2021	₹1m	n/a	₹20m
Dec 31 2020	n/a	n/a	₹20m
Sep 30 2020	n/a	n/a	₹17m
Jun 30 2020	n/a	n/a	₹17m
Mar 31 2020	₹1m	₹1m	₹19m
Dec 31 2019	n/a	n/a	₹32m
Sep 30 2019	n/a	n/a	₹39m
Jun 30 2019	n/a	n/a	₹53m
Mar 31 2019	n/a	n/a	₹45m
Dec 31 2018	n/a	n/a	₹41m
Sep 30 2018	n/a	n/a	₹26m
Jun 30 2018	n/a	n/a	₹8m
Mar 31 2018	₹1m	₹1m	₹18m

Compensación vs. Mercado: La compensación total de Daulat($USD14.40K) está por debajo de la media de empresas de tamaño similar en el mercado Indian ($USD39.58K).

Compensación vs. Ingresos: La compensación de Daulat ha sido consistente con los resultados de la empresa en el último año.

CEO

Daulat Medhora (78 yo)

14.3yrs

Permanencia

₹1,200,000

Compensación

Dr. Daulat N. Medhora serves as Executive Chairman and Joint Managing Director of Fredun Pharmaceuticals Limited since January 01, 2010 and has been its Director since June 08, 1987. Dr. Medhora holds PhD...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Daulat Medhora	Executive Chairman & Joint MD	14.3yrs	₹1.20m	30.02% ₹ 1.2b
Fredun Medhora	MD, CFO & Whole Time Director	9.6yrs	₹5.40m	3.81% ₹ 150.4m
Jinkal Soni	Company Secretary & Compliance Officer	2.3yrs	₹254.40k	sin datos

9.6yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 539730 es experimentado (9.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Daulat Medhora	Executive Chairman & Joint MD	36.9yrs	₹1.20m	30.02% ₹ 1.2b
Fredun Medhora	MD, CFO & Whole Time Director	17.7yrs	₹5.40m	3.81% ₹ 150.4m
Nariman Medhora	Non-Executive Director	8.7yrs	sin datos	15.32% ₹ 604.4m
Aspi Raimalwala	Non-Executive Independent Director	8.7yrs	₹48.00k	0.17% ₹ 6.8m
Rohinton Kanga	Non-Executive Independent Director	8.7yrs	₹48.00k	0.011% ₹ 419.8k
Niharika Agarwal	Additional Director	less than a year	sin datos	sin datos
Daisy Dsouza	Additional Independent Director	less than a year	sin datos	sin datos

8.7yrs

Permanencia media

75yo

Promedio de edad

Junta con experiencia: La junta directiva de 539730 se considera experimentada (8.6 años de antigüedad promedio).

Fredun Pharmaceuticals Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Fredun Pharmaceuticals Limited Announces Appointment of Ms. Daisy Cyril Dsouza as Additional Independent Director

Fredun Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2023

Fredun Pharmaceuticals Limited Approves the Resignation of Dr. Chandrakant Shah as Independent Director

Insufficient new directors

Fredun Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2022

Insufficient new directors

Recent updates

New minor risk - Shareholder dilution

Fredun Pharmaceuticals Limited Proposes Final Dividend for the Financial Year 2023-24

New major risk - Financial position

Full year 2024 earnings released: EPS: ₹33.32 (vs ₹24.13 in FY 2023)

Investor sentiment improves as stock rises 22%

Fredun Pharmaceuticals Limited to Report Fiscal Year 2024 Results on May 07, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 23%

Fredun Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Fredun Pharmaceuticals Limited Announces Appointment of Ms. Daisy Cyril Dsouza as Additional Independent Director

Second quarter 2024 earnings released: EPS: ₹8.40 (vs ₹7.11 in 2Q 2023)

Fredun Pharmaceuticals Limited Proposes Dividend for the Financial Year Ended March 31, 2023

Fredun Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 24%

Fredun Pharmaceuticals Limited Approves the Resignation of Dr. Chandrakant Shah as Independent Director

First quarter 2024 earnings released: EPS: ₹5.24 (vs ₹2.12 in 1Q 2023)

Fredun Pharmaceuticals Limited to Report Q1, 2024 Results on Jul 19, 2023

Full year 2023 earnings released: EPS: ₹22.93 (vs ₹14.29 in FY 2022)

Fredun Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2022-23

Fredun Pharmaceuticals Limited to Report Q4, 2023 Results on May 24, 2023

Investor sentiment improves as stock rises 20%

Third quarter 2023 earnings released: EPS: ₹7.66 (vs ₹4.22 in 3Q 2022)

Fredun Pharmaceuticals Limited to Report Q3, 2023 Results on Jan 27, 2023

Insufficient new directors

Fredun Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 10, 2022

Investor sentiment improved over the past week

Fredun Pharmaceuticals Limited Approves Dividend for the Financial Year Ended March 31, 2022

Fredun Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2022

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: ₹2.12 (vs ₹0.82 in 1Q 2022)

Fredun Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 12, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Fredun Pharmaceuticals Limited Approves Dividend for the Financial Year 2021-22

Fredun Pharmaceuticals Limited to Report Q4, 2022 Final Results on May 16, 2022

Insufficient new directors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Fredun Pharmaceuticals Limited Approves Appointment of Jinkal Shah as Company Secretary and Compliance Officer

Second quarter 2022 earnings released: EPS ₹4.61 (vs ₹2.07 in 2Q 2021)

Fredun Pharmaceuticals Limited announced that it expects to receive INR 106.119316 million in funding from Systematix Fincorp India Ltd, Subir Diamonds Pvt. Ltd and other investors

Investor sentiment improved over the past week

Upcoming dividend of ₹0.70 per share

Full year 2021 earnings released: EPS ₹5.05 (vs ₹4.77 in FY 2020)

Third quarter 2021 earnings released: EPS ₹3.35 (vs ₹2.55 in 3Q 2020)

New 90-day high: ₹514

Fredun Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 12, 2021

New 90-day high: ₹456

New 90-day high: ₹300

New 90-day high: ₹278

Fredun Pharmaceuticals Limited to Report Q2, 2021 Results on Nov 09, 2020

Upcoming Dividend of ₹0.66 Per Share

Full year earnings released - EPS ₹4.77

Fredun Pharmaceuticals Limited to Report Q1, 2021 Results on Sep 15, 2020

New 90-day high - ₹253

Fredun Pharmaceuticals Limited to Report Q4, 2020 Results on Jul 29, 2020

New 90-day high - ₹207

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad